| A | B |
|---|
| type 1 DM | B cells do not produce any insulin |
| type 2 DM | B cells produce insufficient insulin |
| diet & lifestyle changes | first line of tx for type 2 DM |
| insulin | treatment for type 1 DM |
| oral meds | treatment for type 2 DM |
| 70 - 100 | normal BG level |
| BG levels at consistent level | goal of DM treatment |
| obesity, heart disease | comorbidities of DM |
| hyperglycemia | BS greater than 126 mg/dl |
| hypoglycemia | BS less than 50 mg/dl |
| insulin | hormone which is glucose transporter |
| macroangiopathy | large vessel damage from spiking BS levels |
| microangiopathy | capillary vessel damage from spiking BS levels |
| nerve damage | result of metabolic changes from spiking BS levels |
| onset | time med starts to work |
| peak | time med has greatest effect |
| duration | length of time med has effect |
| 30 days | insulin expiration at room temp storage |
| 90 days | insulin expiration in frig storage |
| aspirin | cause BS to decrease |
| Beta Blockers | cause BS to increase |
| clear solution | fast acting |
| cloudy solution | intermediate or long acting |
| rapid acting | adm within 15 min of meal |
| fast acting | adm within 1 hour of meal |
| intermediate acting | peak 6 hours |
| slow acting | adm same time every 24 hours |
| aspart, lispro | rapid acting insulins |
| regular | short acting insulin |
| NPH | intermediate acting insulin |
| Lantus, Ultralente | slow acting insulins |
| combination insulins | maintain BS now & later |
| clear to cloudy | sequence for drawing up insulins |
| biggest AE of insulin | hypoglycemia |
| glucagon | antihypoglycemic agent |
